Clinical trials
Glioblastoma Multiforme of Brain clinical trials
Below are recruiting glioblastoma multiforme of brain clinical trials, each written for real people, not researchers. We’re tracking 66 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02861898RecruitingPhase 1/Phase 2
Cetuximab delivered into the brain tumor artery for new glioblastoma
This Phase 1/2 study tests whether giving cetuximab directly into the artery that feeds the brain tumor can help people with newly diagnosed glioblastoma. It aims to target the tumor more precisely while checking safety and early signs of benefit.
New York, New YorkAges 18 years+ - NCT07464925RecruitingPhase 1
Testing GLIX1 for adults with returning high-grade glioma
This trial tests a new drug called GLIX1 to find a safe dose for people whose high-grade glioma (a fast-growing brain tumor) has come back or is getting worse after earlier treatments. It may be an option if you've had no more than two prior treatments.
Tampa, FloridaAges 18 years+ - NCT07552233Recruiting
NK Cell Therapy for Recurrent Brain Tumors
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT05116137Enrolling by invitation
Exercise therapy to build muscle after glioblastoma
This trial studies whether a resistance (strength-building) exercise program can help survivors of glioblastoma keep or increase their muscle mass. If you are able to safely exercise, it may support recovery and overall strength after treatment.
Halifax, Nova ScotiaAges 18 years+ - NCT03170141Enrolling by invitationPhase 1
T-cell therapy for recurrent brain tumor
This Phase 1 study tests modified immune T-cells to treat recurrent glioblastoma (a fast-growing brain tumor) that can be seen on scans. Because it’s early-stage, the goal is mainly safety, but you may be helping researchers understand if the treatment can shrink tumors.
Shenzhen, GuangdongAges 6–70 - NCT06595186RecruitingPhase 2
JK-1201I plus temozolomide for newly diagnosed glioblastoma
This trial tests a new drug called JK-1201I combined with the standard chemotherapy temozolomide after you finish your initial radiation and chemo. It is for people with newly diagnosed glioblastoma who have had most of their tumor removed and are now ready for the next phase of treatment.
BeijingAges 18–75 - NCT06059690RecruitingPhase 1/Phase 2
Imaging brain tumors to guide glioblastoma treatment
This trial studies a special imaging scan that combines MRI and PET to find active tumor areas in patients with glioblastoma. It aims to see if the scan can help identify the most aggressive parts of the tumor for surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT06466031Recruiting
PET/MRI for guiding glioblastoma surgery
This trial tests whether a special PET scan combined with MRI can help guide surgery for glioblastoma. It is for people with a newly diagnosed, single tumor who are candidates for surgery.
Lodz, Łódź VoivodeshipAges 18–70 - NCT06632236RecruitingPhase 1
Amivantamab for advanced brain tumors
This trial tests a new drug called amivantamab for people with advanced brain tumors, including glioblastoma. It aims to see if the drug can shrink or slow tumor growth.
CambridgeAges 16 years+ - NCT05353530RecruitingPhase 1
CAR T cell treatment for CD70-positive newly diagnosed glioblastoma
This trial tests a customized immune-cell treatment (CAR T cells) for adults with newly diagnosed glioblastoma (GBM) whose tumors have enough CD70 protein. If you qualify, the goal is to see whether this treatment can better control the cancer by targeting it in the brain.
Gainesville, FloridaAges 18–80 - NCT05474378RecruitingPhase 1
CAR T cell therapy for recurrent glioblastoma
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
Palo Alto, CaliforniaAges 18 years+ - NCT06954636Recruiting
Smell test to predict glioblastoma outcomes (newly diagnosed)
This study looks at whether a simple smell test can help predict how glioblastoma will progress. It is for people who are newly diagnosed and have not started treatment yet.
EssenAges 18 years+ - NCT07326566RecruitingPhase 2
Silevertinib and chemo for a type of glioblastoma
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
Birmingham, AlabamaAges 18 years+ - NCT03175224RecruitingPhase 2
Test drug APL-101 for lung or other tumors with MET changes
This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT03958240Recruiting
Study how cancers trigger the immune system
This study looks at what makes some cancers more “noticeable” to the immune system. It may help researchers design better future immunotherapy by collecting information (often including blood samples) from people with different cancers.
ToulouseAges 18 years+ - NCT05281731Recruiting
Ultrasound-guided “sonobiopsy” for new brain tumor diagnosis
This trial tests a new way to take a tiny tissue sample from a suspected glioblastoma using ultrasound, to improve noninvasive detection. You may be able to get this targeted sample while you’re already planning surgery for tumor removal.
St Louis, MissouriAges 18 years+ - NCT07733674RecruitingPhase 1
Testing a new imaging agent for brain and pancreatic tumors
This early-phase study tests a new imaging agent that may help see certain solid tumors (like brain cancer or pancreatic cancer) more clearly. You will receive a single injection of a radioactive tracer, then have several scans over a few days to see where the tracer goes and how long it stays.
Houston, TexasAges 18 years+ - NCT03005132Recruiting
Study for people with newly diagnosed brain cancer (GBM)
This trial looks at people with glioblastoma (GBM), a fast-growing brain tumor, to better understand it and how treatments might work. You may be able to join if you’re in a good general health range and have not had prior cancer chemotherapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06533163Recruiting
Magnetic therapy for new glioblastoma
This trial tests a new low-intensity magnetic treatment (like a gentle magnetic pad placed on your head) for people with a newly diagnosed, aggressive brain tumor called glioblastoma. It aims to see if different amounts of exposure to this therapy are safe and help slow tumor growth.
Stuttgart, Baden-WurttembergAges 18 years+ - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Aurora, ColoradoAges 1–39 - NCT05843253RecruitingPhase 2
Ribociclib plus everolimus or temozolomide for certain brain tumors
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Aurora, ColoradoAges 1–39 - NCT06016452RecruitingPhase 2
Chlorophyllin for brain radiation damage in glioma patients
This trial tests if chlorophyllin can help manage brain damage caused by radiation therapy in people with diffuse glioma. It may reduce symptoms or prevent them from getting worse.
Mumbai, MaharashtraAges 18–70 - NCT05565326Recruiting
Testing MR-guided radiation checks for glioblastoma
This study tests how best to measure and track glioblastoma treatment while using MRI (a body scanner) to guide radiation. It may help improve how doctors assess the radiation response during therapy.
Zurich, Canton of ZurichAges 18 years+ - NCT06118723Recruiting
Supramaximal vs maximal surgery for brain tumors
This trial compares removing as much tumor as safely possible (supramaximal resection) with standard maximal resection in people with high-grade glioma (an aggressive brain tumor). The goal is to see if more extensive removal improves survival and quality of life.
San Francisco, CaliforniaAges 18–90
Hear when a new Glioblastoma Multiforme of Brain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glioblastoma multiforme of brain?
- Yes. Clin2 currently lists 66 recruiting glioblastoma multiforme of brain studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioblastoma multiforme of brain trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioblastoma multiforme of brain trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.